Literatur
-
1
Atreya R, Mudter J, Finotto S. et al .
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Nat Med.
2000;
6
583-588
-
2
Ghosh S, Goldin E, Gordon F H. et al .
Natalizumab for active Crohn’s disease.
N Engl J Med.
2003;
348
24-32
-
3
Hanauer S B, Feagan B G, Lichtenstein G R. et al .
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.
Lancet.
2002;
359
1541-1549
-
4
Hoffmann J C, Zeitz M.
Standardtherapie bei Morbus Crohn.
Internist.
2002;
43
1376-1385
-
5
Hommes D, van den Blink B, Plasse T. et al .
Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease.
Gastroenterology.
2002;
122
7-14
-
6
Ito H, Takazoe M, Fukuda Y, Hibi T. et al .
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease.
Gastroenterology.
2004;
126
989-996; discussion 947.
-
7
Neurath M F, Pettersson S, Meyer zum Buschenfelde K H, Strober W.
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice.
Nat Med.
1996;
2
998-1004
-
8
Present D H, Rutgeerts P, Targan S. et al .
Infliximab for the treatment of fistulas in patients with Crohn’s disease.
N Engl J Med.
1999;
340
1398-1405
-
9
Sandborn W J, Hanauer S B, Katz S. et al .
Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial.
Gastroenterology.
2001;
121
1088-1094
-
10
Summers R W, Elliott D E, Qadir K, Urban J F, Thompson R, Weinstock J V.
Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
Am J Gastroenterol.
2003;
98
2034-2041
-
11
Targan S R, Hanauer S B, van Deventer S J. et al .
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group.
N Engl J Med.
1997;
337
1029-1035
-
12
Yacyshyn B R, Bowen-Yacyshyn M B, Jewell L, Tami J A, Bennett C F, Kisner D L, Shanahan W RJ.
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease.
Gastroenterology.
1998;
114
1133-1142
Priv.-Doz. Dr. J. C. Hoffmann
Medizinische Klinik I mit Schwerpunkt Gastroenterologie/Infektiologie/Rheumatologie, Universitätsmedizin Berlin, Campus Benjamin Franklin
Hindenburgdamm 30
12200 Berlin
Phone: +49/30/84453950
Fax: +49/30/84454481
Email: joerg.hoffmann@charite.de
